Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal …
S Giuntini, DC Reason, DM Granoff - Infection and immunity, 2012 - Am Soc Microbiol
Meningococcal vaccines containing factor H binding protein (fHbp) are in clinical development.
fHbp binds human fH, which enables the meningococcus to resist complement-mediated …
fHbp binds human fH, which enables the meningococcus to resist complement-mediated …
Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2
O Koeberling, S Giuntini, A Seubert… - Clinical and Vaccine …, 2009 - Am Soc Microbiol
Meningococcal outer membrane vesicle (OMV) vaccines, which are treated with detergents
to decrease endotoxin activity, are safe and effective in humans. However, the vaccines elicit …
to decrease endotoxin activity, are safe and effective in humans. However, the vaccines elicit …
Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding
S Giuntini, DC Reason, DM Granoff - Infection and immunity, 2011 - Am Soc Microbiol
Binding of the complement-downregulating protein factor H (fH) to the surface of the
meningococcus is important for survival of the organism in human serum. The meningococcal …
meningococcus is important for survival of the organism in human serum. The meningococcal …
Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity
S Giuntini, R Pajon, S Ram, DM Granoff - Infection and immunity, 2015 - Am Soc Microbiol
Among 25 serogroup B Neisseria meningitidis clinical isolates, we identified four (16%) with
high factor H binding protein (FHbp) expression that were resistant to complement-mediated …
high factor H binding protein (FHbp) expression that were resistant to complement-mediated …
Oral administration of an anti-CfaE secretory IgA antibody protects against Enterotoxigenic Escherichia coli diarrheal disease in a nonhuman primate model
…, C Gaspar, J Regeimbal, RG Nunez, S Giuntini… - Vaccine, 2020 - Elsevier
Enterotoxigenic Escherichia coli (ETEC) is a leading cause of diarrhea-associated illness in
developing countries. There is currently no vaccine licensed to prevent ETEC and the …
developing countries. There is currently no vaccine licensed to prevent ETEC and the …
Serum bactericidal antibody responses of adults immunized with the MenB-4C vaccine against genetically diverse serogroup B meningococci
MenB-4C is a meningococcal vaccine for the prevention of serogroup B disease. The vaccine
contains factor H binding protein (FHbp) and three other antigens that can elicit serum …
contains factor H binding protein (FHbp) and three other antigens that can elicit serum …
Identification and characterization of human monoclonal antibodies for immunoprophylaxis against enterotoxigenic Escherichia coli infection
S Giuntini, M Stoppato, M Sedic, M Ejemel… - Infection and …, 2018 - Am Soc Microbiol
Enterotoxigenic Escherichia coli (ETEC) causes diarrheal illness in infants in the developing
world and travelers to countries where the disease is endemic, including military personnel. …
world and travelers to countries where the disease is endemic, including military personnel. …
[HTML][HTML] Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design
…, Q Li, CT McMahon, M Stoppato, S Giuntini… - Scientific reports, 2021 - nature.com
Enterotoxigenic Escherichia coli (ETEC) is estimated to cause approximately 380,000
deaths annually during sporadic or epidemic outbreaks worldwide. Development of vaccines …
deaths annually during sporadic or epidemic outbreaks worldwide. Development of vaccines …
Binding of complement factor H (FH) decreases protective anti-FH binding protein antibody responses of infant rhesus macaques immunized with a meningococcal …
DM Granoff, I Costa, M Konar, S Giuntini… - The Journal of …, 2015 - academic.oup.com
Background. The meningococcal vaccine antigen, factor H (FH)–binding protein (FHbp),
binds human complement FH. In human FH transgenic mice, binding decreased protective …
binds human complement FH. In human FH transgenic mice, binding decreased protective …
[HTML][HTML] Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding
DM Granoff, S Giuntini, FA Gowans, E Lujan… - JCI insight, 2016 - ncbi.nlm.nih.gov
Meningococcal factor H-binding protein (FHbp) is an antigen in 2 serogroup B meningococcal
vaccines. FHbp specifically binds human and some nonhuman primate complement FH. …
vaccines. FHbp specifically binds human and some nonhuman primate complement FH. …